Spots Global Cancer Trial Database for anaplastic lymphoma kinase (alk)
Every month we try and update this database with for anaplastic lymphoma kinase (alk) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | NCT01401504 | Solid Tumor | ASP3026 | 20 Years - | Astellas Pharma Inc | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | NCT01401504 | Solid Tumor | ASP3026 | 20 Years - | Astellas Pharma Inc | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | NCT02784158 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib | 18 Years - | Takeda | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | NCT01401504 | Solid Tumor | ASP3026 | 20 Years - | Astellas Pharma Inc | |
| Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma) | NCT01284192 | Advanced Malign... Positive for An... Positive for Pr... Solid Tumor B-Cell Lymphoma | ASP3026 | 18 Years - | Astellas Pharma Inc | |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | NCT01772797 | Anaplastic Lymp... Non-small Cell ... | LDK378 AUY922 | 18 Years - | Novartis | |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | NCT06074588 | Non-small Cell ... | Sacituzumab tir... Docetaxel Pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | NCT01401504 | Solid Tumor | ASP3026 | 20 Years - | Astellas Pharma Inc | |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | NCT03194893 | Neoplasms | Alectinib Crizotinib | - | Hoffmann-La Roche | |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | NCT02784158 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
